JP2006232679A - バナジウムイオン含有高血圧及び高中性脂肪血症改善剤並びに高中性脂肪血症患者用血糖降下剤 - Google Patents
バナジウムイオン含有高血圧及び高中性脂肪血症改善剤並びに高中性脂肪血症患者用血糖降下剤 Download PDFInfo
- Publication number
- JP2006232679A JP2006232679A JP2005045597A JP2005045597A JP2006232679A JP 2006232679 A JP2006232679 A JP 2006232679A JP 2005045597 A JP2005045597 A JP 2005045597A JP 2005045597 A JP2005045597 A JP 2005045597A JP 2006232679 A JP2006232679 A JP 2006232679A
- Authority
- JP
- Japan
- Prior art keywords
- vanadium
- concentration
- agent
- fat
- neutral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910001456 vanadium ion Inorganic materials 0.000 title claims abstract description 36
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 18
- 239000008280 blood Substances 0.000 title claims abstract description 6
- 210000004369 blood Anatomy 0.000 title claims abstract description 6
- 201000005577 familial hyperlipidemia Diseases 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 16
- 239000003472 antidiabetic agent Substances 0.000 claims description 8
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 230000010030 glucose lowering effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 39
- 201000010099 disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 230000035622 drinking Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000243 solution Substances 0.000 abstract description 2
- 239000011575 calcium Substances 0.000 description 22
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 21
- 229910052720 vanadium Inorganic materials 0.000 description 18
- 230000036772 blood pressure Effects 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000010355 oscillation Effects 0.000 description 8
- 230000001766 physiological effect Effects 0.000 description 8
- 235000010724 Wisteria floribunda Nutrition 0.000 description 7
- 239000003651 drinking water Substances 0.000 description 7
- 235000020188 drinking water Nutrition 0.000 description 7
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 4
- MCPTUMJSKDUTAQ-UHFFFAOYSA-N vanadium;hydrate Chemical compound O.[V] MCPTUMJSKDUTAQ-UHFFFAOYSA-N 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 2
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 210000000885 nephron Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000003681 vanadium Chemical class 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000017063 Catecholamine Receptors Human genes 0.000 description 1
- 108010013659 Catecholamine Receptors Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 description 1
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010042666 Sweating fever Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000492 insulin antagonist Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- -1 vanadyl chloride Chemical compound 0.000 description 1
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 1
- 229940041260 vanadyl sulfate Drugs 0.000 description 1
- 229910000352 vanadyl sulfate Inorganic materials 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005045597A JP2006232679A (ja) | 2005-02-22 | 2005-02-22 | バナジウムイオン含有高血圧及び高中性脂肪血症改善剤並びに高中性脂肪血症患者用血糖降下剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005045597A JP2006232679A (ja) | 2005-02-22 | 2005-02-22 | バナジウムイオン含有高血圧及び高中性脂肪血症改善剤並びに高中性脂肪血症患者用血糖降下剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006232679A true JP2006232679A (ja) | 2006-09-07 |
| JP2006232679A5 JP2006232679A5 (https=) | 2008-04-03 |
Family
ID=37040734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005045597A Pending JP2006232679A (ja) | 2005-02-22 | 2005-02-22 | バナジウムイオン含有高血圧及び高中性脂肪血症改善剤並びに高中性脂肪血症患者用血糖降下剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2006232679A (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1827463A1 (en) * | 2004-12-16 | 2007-09-05 | Genmedica Therapeutics SL | Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006035047A (ja) * | 2004-07-23 | 2006-02-09 | Shimizu Corp | バナジウム含有水の製造方法 |
-
2005
- 2005-02-22 JP JP2005045597A patent/JP2006232679A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006035047A (ja) * | 2004-07-23 | 2006-02-09 | Shimizu Corp | バナジウム含有水の製造方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1827463A1 (en) * | 2004-12-16 | 2007-09-05 | Genmedica Therapeutics SL | Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ioannidis | Diabetes treatment in patients with renal disease: Is the landscape clear enough? | |
| Meyers | Pediatric fluid and electrolyte therapy | |
| US20180055797A1 (en) | Non-racemic ketone salts for rapid-onset nutritional ketosis and metabolic therapy | |
| Couri et al. | Mönckeberg's sclerosis–is the artery the only target of calcification? | |
| CN103987281B (zh) | 用于抑郁症和焦虑症的饮食控制的医疗食品及其方法 | |
| Nazamuddin et al. | Concept of diabetes in Unani system of medicine: an overview | |
| JP2023506322A (ja) | リチウムイオン組成物及びその使用 | |
| CN109069532A (zh) | 含铬组合物用于改善健康和健身 | |
| JP2006232679A (ja) | バナジウムイオン含有高血圧及び高中性脂肪血症改善剤並びに高中性脂肪血症患者用血糖降下剤 | |
| Gochhayat et al. | Thiamine: A key role in human health | |
| RU2242236C1 (ru) | Способ инфузионной терапии при кетоацидотической коме у больных с сахарным диабетом | |
| Czerwinski et al. | Safety and efficacy of zinc sulfate in geriatric patients | |
| JP2007031282A (ja) | バナジウムイオンを含有する糖、脂質、及び／又は窒素代謝疾患の改善剤 | |
| EP0990441A1 (en) | A drug for treating diabetic nephrosis | |
| CN105982921A (zh) | 一种治疗痛风的组合物及其应用 | |
| CN104138389B (zh) | 治疗血液循环障碍类疾病的药物组合物 | |
| Hanada et al. | Calcium-alkali syndrome due to vitamin D administration and magnesium oxide administration | |
| CN107279620A (zh) | 一种电解质饮料组合物及其制备方法 | |
| RU2761727C1 (ru) | Способ коррекции ожирения абдоминального типа и метаболического синдрома | |
| EP2051717B1 (en) | Replacing heart surgery by micronutrient | |
| JPS5962526A (ja) | 人体の体質改善用無機質保健剤 | |
| JP2008013469A (ja) | 海洋ミネラル成分からなる骨粗鬆症治療および／または予防剤 | |
| US3565560A (en) | Pharmaceutical preparation containing hydrofuramide and method of using it | |
| KR20100017460A (ko) | 피피에이알 감마 작용물질로 인한 부작용의 예방에 유용한 조성물 | |
| US20100055204A1 (en) | Use of hydrochloric acid in the manufacture of medicament for treating disease caused by fouling of transport tract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110524 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111011 |